Phibro Animal Health Q2 revenue beats amid EBITDA miss and Brazil regulatory headwinds
Phibro Animal Health reported $396.7 million in revenue, beating estimates by 6.8% and rising 4.8% year over year, but adjusted EBITDA of $55.9 million missed forecasts. Operating margin increased to 12.2%. The company’s 2027 EBITDA guidance of $263 million fell slightly below estimates as Zoetis MFA integration faced cost pass-through gaps, and it assumes minimal Brazil virginiamycin contribution pending regulatory review.